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Abstract
Background: This study describes the post-diagnosis care-seeking costs incurred by people living with
TB and/or HIV and their households, in order to identify the potential benefits of integrated care.
Methods: We conducted a cross-sectional study with 454 participants with TB or HIV or both in
public primary health care clinics in Ekurhuleni North Sub-District, South Africa. We collected infor-
mation on visits to health facilities, direct and indirect costs for participants and for their guardians
and caregivers. We define ‘integration’ as receipt of both TB and HIV services at the same facility,
on the same day. Costs were presented and compared across participants with TB/HIV, TB-only
and HIV-only. Costs exceeding 10% of participant income were considered catastrophic.
Results: Participants with both TB and HIV faced a greater economic burden (US$74/month) than
those with TB-only (US$68/month) or HIV-only (US$40/month). On average, people with TB/HIV made
18.4 visits to health facilities, more than TB-only participants or HIV-only participants who made 16
and 5.1 visits, respectively. However, people with TB/HIV had fewer standalone TB (10.9) and HIV (2.2)
visits than those with TB-only (14.5) or HIV-only (4.4). Although people with TB/HIV had access to ‘inte-
grated’ services, their time loss was substantially higher than for other participants. Overall, 55% of
participants encountered catastrophic costs. Access to official social protection schemes was minimal.
Conclusions: People with TB/HIV in South Africa are at high risk of catastrophic costs. To some extent,
integration of services reduces the number of standalone TB and HIV of visits to the health facility. It is
however unlikely that catastrophic costs can be averted by service integration alone. Our results point
to the need for timely social protection, particularly for HIV-positive people starting TB treatment.
Keywords: HIV, integration, patient costs, poverty, tuberculosis
Key Messages
• People with both TB and HIV in South Africa are at high risk of catastrophic costs.
• Integration of services has to some extent reduced the number standalone TB and HIV visits to the health facility. It is,
however, unlikely that catastrophic cost can be averted by service integration alone.
• Social and income protection policies are likely to be required to protect TB/HIV patients if global targets on catastrophic
cost reduction are to be met.
VC The Author 2016. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine. All rights reserved.
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Introduction
The launch of the sustainable development goals and Universal
Health Coverage reflect an increased global focus on the interaction
between health outcomes and poverty. Health sector policymakers
are becoming increasingly interested in interventions and service de-
livery models that may best prevent impoverishment. While there
has been much investigation into the impact of service integration
on provider costs, much less attention has been focussed on the po-
tential economic and poverty reduction benefits to service users, par-
ticularly vulnerable groups (World Bank 2009; World Health
Organization et al. 2009; Atun et al. 2010).
Household and patient-incurred costs associated with health
shocks have long been recognized as key contributors to impoverish-
ment (Heltberg and Lund 2009; Alam and Mahal 2014; Wagstaff
and Lindelow 2014). In the case of TB, patient-incurred costs are a
major barrier to access to health services in low-income countries
(Ensor and Cooper 2004; O’Donnell et al. 2007), and have been
associated with negative TB treatment outcomes (Wingfield et al.
2014). Even where TB services are offered free of charge, the high
costs of access such as transportation and opportunity cost of time
spent accessing care may provide obstacles for vulnerable groups,
while worsening or creating poverty in those that proceed to seek
care (Xu et al. 2007). When faced with high costs of accessing TB
care and a reduced ability to earn income due to illness, some TB pa-
tients resort to selling off their assets and taking interest-bearing
loans (Lo¨nnroth et al. 2014). This can result in a long-term poverty
impact for both patients and their households (Xu et al. 2003;
Gottret and Schieber 2006; WHO 2010; Lo¨nnroth et al. 2014).
For people accessing care for both TB and HIV, health service in-
tegration has the potential to reduce this economic burden.
Integration may benefit patients by enabling health improvements
and cost reductions through less fragmented services, improved con-
tinuity of care and better retention in care (Sweeney et al. 2012).
Integration may also facilitate cost reductions through fewer visits
to facilities and reduced delays in accessing treatment (Legido-
Quigley et al. 2013).
In 2012, TB was the primary cause of death for 25% of all HIV-
associated deaths in South Africa, and 61% of all people with TB
were HIV-positive (WHO 2015). The country has developed guide-
lines for the integration of TB and HIV services with preference for
a ‘one-stop shop’, where services are provided under one roof
(National Department of Health 2011). TB/HIV integration is ex-
pected to ‘ensure comprehensive management of the patient, reduce
morbidity and mortality and improve treatment outcomes’ (Chehab
et al. 2013; National Department of Health 2014). Integration how-
ever remains poorly implemented in South Africa (Churchyard et al.
2014). Although services are commonly provided ‘under one roof’,
they may often not be provided by a single provider, nor will pa-
tients be correctly referred between providers. As a result, the evi-
dence base on the impact of TB/HIV integration on patient-relevant
outcomes is small and inconsistent (Kaplan et al. 2014; Jacobson
et al. 2015; Ledibane et al. 2015).
To date, TB patient costing studies in South Africa (Chimbindi
et al. 2015; Foster et al. 2015) have not comprehensively assessed
the economic impact of illness on people with both TB and HIV.
The purpose of this paper is to comprehensively describe the post-
diagnosis care-seeking behaviour, patient costs incurred and coping
strategies adopted by people living with TB and/or HIV and their
households, in order to identify the potential benefits of integrated
care. To present this, we collected data on the costs incurred by par-
ticipants in the period immediately following receipt of a TB and/or
HIV diagnosis and including the first 3–5 months of care, as this is
the period when previous studies have shown patients to incur the
highest costs (Foster et al. 2015). We present this evidence in order
to support policy makers as they assess the potential benefits from
the improved implementation of TB/HIV integration.
Methods
Study setting
The study was conducted in Ekurhuleni North; a sub-district in
Gauteng province, South Africa. Ekurhuleni had approximately 3.2
million inhabitants in 2013 (City of Ekurhuleni 2013) and a popula-
tion density of approximately 1609 people per square kilometre
(Statistics South Africa 2015). Ekurhuleni has high unemployment
rates of 28.8% in the general population and 36.9% among persons
between the ages of 15 and 35 (City of Ekurhuleni 2013, 2014). In
2013, 8% of the people living in Ekurhuleni reported that they did
not have any source of income and 27.9% were considered to be liv-
ing below a nationally defined minimum living standard (City of
Ekurhuleni 2013). The South Africa District Health Barometer of
2013 estimated a TB case notification rate of 336 per 100 000 for
Ekurhuleni (Massyn et al. 2014). According to a national HIV
prevalence, incidence and behaviour survey, the HIV prevalence for
Ekurhuleni was 14.3% (10.3–19.5%) in 2012 (Simbayi et al. 2014).
Study design and baseline data collection
This was a cross-sectional study nested within a cluster randomized
trial—the MERGE trial. The MERGE trial evaluated the effect of
implementing an intervention to optimize/improve TB/HIV integra-
tion on morbidity, mortality and retention in care at public primary
health care (PHC) clinics (Kufa et al. 2014). A total of 18 PHC clin-
ics, the study clinics, were randomly allocated to the intervention or
control arm. To be eligible for inclusion in the trial, the clinics had
to meet the following criteria: no conflicting research study in pro-
gress at the clinic, clinic has at least 40 TB cases per year and the
clinic has available TB data.
Participation in the MERGE trial was not a requirement for in-
clusion in the patient costs study. Instead MERGE trial participants
had an equal chance of also being enrolled in the patient costs study
if eligible. Cost data were collected using structured questionnaires
at the 18 study clinics between April and October 2013. Participants
were selected consecutively and enrolled if they met any one of the
following criteria: (1) received a TB diagnosis 3–5 months prior to
interview and had a positive HIV test at any time (‘TB/HIV’); (2)
received a TB diagnosis 3–5 months prior to interview and was HIV
negative at time of enrolment (‘TB-only’); and (3) tested HIV posi-
tive for the first time 3–5 months prior to interview and was not on
treatment for TB at the time of enrolment (‘HIV-only’). The time
period was informed by previous research that showed that partici-
pant recall becomes diminished at around 4 months onwards
(Mauch et al. 2011). All participants reported a known positive or
negative HIV status. Unlike TB, HIV positive reporting was not con-
firmed with clinic records. Participant numbers were capped at 50
per site, although only 3 of 18 sites reached this cap due to low par-
ticipant numbers at the facilities.
Questionnaires
Questionnaires were adapted from the Tool to Estimate Patients’
Costs that was developed by the Tuberculosis Coalition for
Technical Assistance and the United States Agency for International
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Development (USAID and TBCTA 2008). Separate questionnaires
were developed for people being treated for TB (regardless of HIV
status) and for HIV-positive people not being treated for TB to ac-
commodate different pathways of care. Both questionnaires cap-
tured similar level of detail on the different events in the pathway of
care. Questionnaires focused on the period in the first 3–5 months
after participants were told they had TB (‘post-diagnosis’) to under-
stand the costs of accessing integrated services.
Demographic characteristics such as gender, age, ethnicity and
nationality, levels of education, marital status, employment at the
time of receipt of diagnosis and the impact of illness on normal pro-
ductive patterns were collected. Questionnaires also included de-
tailed questions on the number of visits made to a range of
providers, including the participant’s local PHC clinic (our study
clinic), other public facilities, general practitioners, hospitals, trad-
itional healers and pharmacies. A distinction was made between
integrated visits and stand-alone visits for TB and/or HIV services at
the study clinic. We define ‘integration’ as physical and temporal in-
tegration, or receipt of both TB and HIV services at the same facil-
ity, on the same day (Mayhew et al. 2016).
It was not feasible to measure costs for every visit made by par-
ticipants; questions therefore elicited estimates of direct costs, time
spent and income loss for the most recent visit to each provider, and
the number of visits made to each provider type during the treatment
period. The questionnaires also captured information about strat-
egies adopted by participants to cope with costs of illness. Coping
strategies enquired of include: taking interest-bearing loans from
lenders, borrowing money from friends or relatives, selling personal
goods and receipt of grants or charitable donations.
Data analysis
The data were captured in a secure electronic database and exported
into Stata 14 and Microsoft Excel for analysis (Microsoft 2014;
Stata Corp 2015). An ‘available case analysis’ assumed that unavail-
able data values were missing at random. All costs were converted
to an average monthly cost to facilitate comparison across partici-
pants who had received diagnosis between 3 and 5 months prior to
interview.
Direct costs were defined as medical and non-medical expenses
paid out-of-pocket (OOP). Medical expenses included consult-
ation fees and any OOP payment for medicines and diagnostics
paid at any provider. Direct non-medical expenses included the
travel costs of participants and guardians if any, food costs
incurred while in hospital, money spent buying any special foods
or dietary supplements due to illness, and any interest incurred on
loans taken out to meet the costs of OOP payments. Direct medical
and non-medical costs were determined as the product of the re-
ported expense for the most recent visit to each provider type and
the number of visits made to that provider during the post-
diagnosis period; these were then divided by the number of months
in the post-diagnosis period.
We use reported income loss as our primary measure of indirect
costs for participants. To facilitate comparison with other patient
cost studies, we also report separately on time the participants spent
seeking care or unable to work. We estimated the mean time spent
per month using the total time reported for the most recent visit to
each provider, multiplied by the total monthly visits to each pro-
vider. Indirect costs for guardians and carers were defined as the op-
portunity cost of time spent away from their daily productive
routine, including travel to health facilities, consultation time, and
covering household chores usually done by the participant. As
guardians and carers were not interviewed directly about their in-
come loss, the opportunity cost of this time for guardians and carers
was estimated using median income of elementary occupations in
South Africa, R 1517 per month (Statistics South Africa 2010) mul-
tiplied by their estimated time loss. Loan costs were calculated as
the difference between the borrowed amount and the amount paid
back.
We also estimated catastrophic costs incurred due to TB and/or
HIV. The principle of catastrophic costs is rooted in identifying
when patients and their households involuntarily reduce expenditure
on basic household needs such as food, clothing and education in
order to pay for health care (Ranson 2002). According the World
Health Organization (WHO) approach, costs are defined as cata-
strophic when total costs incurred (direct and indirect combined) ex-
ceed a given threshold of household income (World Health
Organization 2015). In the absence of reliable data on household in-
come, we adopted a threshold of 10% of individual participant in-
come (Barter et al. 2012). This threshold has been a widely used
benchmark for catastrophic costs in many patient costing studies
(Xu et al. 2003; Russell 2004; Tanimura et al. 2014; Wingfield et al.
2014; Foster et al. 2015) due to the challenges of measuring house-
hold rather than individual income. An alternative 20% threshold of
household income is also being increasingly used in the case of TB,
due to an observed association between this level of cost and nega-
tive health outcomes in Peru (Wingfield et al. 2014). We varied the
catastrophic cost threshold in our analysis from 5 to 25% to under-
stand the impact of this arbitrary threshold (Russell 2004; Ukwaja
et al. 2013). To avoid mathematical errors associated with division
by zero, an arbitrary value of USD1 was assigned to income for
those participants who reported zero income or where income was a
missing value (Foster et al. 2015).
We adopted a descriptive cost analysis due to the small sample
size of some of the comparison groups. Prior to analysis, all costs
were converted from the South African rand (ZAR) to the United
States dollar (USD) using the average rate during the period of
data collection in 2013; ZAR 9.62 ¼ US$1 (OANDA 2016).
Despite skewness and non-normality of cost data, arithmetic
means were used in all calculations as was done in the previous
studies (Wingfield et al. 2014) and in line with the principles of
economic evaluation (Bill and Melinda Gates Foundation et al.
2014). Standard deviations were used as measures of dispersion
for cost data and inter-quartile ranges for continuous descriptive
data.
Ethical considerations
Ethical approval was obtained from The London School of Hygiene
& Tropical Medicine and the University of the Witwatersrand. The
study was also registered in the clinical trials register for South
Africa (registration number DOH-27-10113846) and additional
permission to conduct the study was sought from the Ekurhuleni
health department.
Results
We invited 475 participants meeting the inclusion criteria to partici-
pate in the study and 463 consented to participate. The most com-
mon reason for non-inclusion was receipt of diagnosis outside of the
window of 3–5 months prior to interview. Of the 463 enrolled, 454
participants from 18 PHC clinics were included in the analysis, with
9 participants excluded because data on their gender were missing at
analysis stage. The majority of the participants included in the
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analysis had received a diagnosis of HIV-only (n ¼ 298; 66% of
sample). Forty TB-only participants and 116 TB/HIV participants
were recruited. Of the TB/HIV participants, 20 received both TB
and HIV diagnoses on the same day and an additional 46 received
both diagnoses within 2 months of each other.
Descriptive characteristics
Characteristics of the study population are presented in Table 1.
The majority of participants was unmarried (58%). Most partici-
pants were female (64%) and educated above grade 8 (84%).
Participants born in South Africa and those of African origin made
up 83 and 97% of the study population, respectively.
Unemployment was very high across all participant groups; 45% of
enrolled participants were unemployed at the time of receiving their
diagnosis, as compared to a national unemployment rate of 25%
(Statistics South Africa 2015). Median monthly income was $128 at
the time of diagnosis with TB and/or HIV. Of those who were em-
ployed at the time of diagnosis, 6% had a monthly income below
the national poverty line of $52 per month (Statistics South Africa
2014). The highest income at the time of diagnosis was reported by
the TB/HIV group (median $150 per month), while the TB-only
group had the lowest average income ($88 per month).
A large proportion of participants had informal carers; 55% of
those with TB-only, 37% of those with HIV-only and 48% of those
with TB/HIV. The impact of illness and care-seeking had variable ef-
fects on participants’ and household members’ income-earning
activities. Across all participant groups, 19% of participants missed
work due to illness and 21% of participants were unable to com-
plete their normal household duties in the post-diagnosis period.
People with TB were more likely to miss work with the highest pro-
portion being 31% among TB/HIV participants.
Health service use
All study facilities offered integrated care for both TB and HIV as
defined in the methods section. Actual practice at study facilities var-
ied considerably; in some facilities visits were integrated at the pro-
vider level where both services were delivered by the same provider or
the consultation level where both services were delivered within the
same consultation, though the latter was rare. Table 2 shows the over-
all mean number of clinic visits and by visit type, for each participant
group. TB/HIV participants on average made five ‘integrated’ visits in
the post-diagnosis period. TB-only participants also received inte-
grated visits when testing for HIV and collecting test results—on aver-
age this was 0.8 visits per person across study facilities.
In the post-diagnosis period, all participants made relatively few
visits to providers outside the public health system. The average
total number of visits to other facilities and providers ranged from
0.6 in the TB-only group to 0.2 in the HIV-only group. The total
number of participants accessing other types of health provider, and
mean number of visits by those participants, is presented in
Supplementary Table S2. The largest proportion of participants ac-
cessing care from providers outside the public health system was
among the TB/HIV participant group, at 23%. Fifteen percent of
TB-only participants and 14% of HIV-only participants reported
use of providers outside the public health system respectively.
Thirteen TB/HIV participants were hospitalized, as compared to
two HIV-only participants and zero TB-only participants.
All people with TB visited the study health facilities at least four
times per month in the post-diagnosis period. HIV-only participants
made the fewest visits to study facilities over the study period (mean
1 visit per month).
Patient costs
Table 3 presents patient-incurred costs in the post-diagnosis period.
The highest total costs in the post-diagnosis period were reported by
TB/HIV and TB-only participants; $74.07 and $68.33 per month,
respectively. Costs for the HIV-only group ($40.41 per month) were
substantially lower. Indirect costs contributed the majority of the
total costs, at 71% of total cost for TB/HIV participants, 86% of
total cost for TB-only participants and 55% of total cost for HIV-
only participants.
Direct OOP costs incurred by participants ranged from $9.86
per month for TB-only participants to $21.72 per month for TB/
HIV participants (Table 3). Detailed costs incurred at all facility
types are listed in Supplementary Table S2. Direct costs were largely
driven by costs of special food purchased as nutritional supplements
for the illnesses in question. Monthly costs of special foods ranged
from $8.06 to $13.40 per month, representing 53% of direct costs
for HIV-only participants, 60% of direct costs for TB/HIV partici-
pants and 82% of direct costs for TB-only participants. Expenditure
Table 1. Demographic characteristics at time of interview, by participant group
TB/HIV TB-only HIV-only
(n ¼ 116) (n ¼ 40) (n ¼ 298)
Female, n (%) 63 22% 16 6% 210 73%
Age, n (%) 18–24 10 9% 5 13% 22 7%
25–34 43 37% 21 53% 131 44%
35–44 48 41% 6 15% 96 32%
45 13 11% 8 20% 43 14%
South African, n (%) 100 86% 32 80% 244 82%
Black/African, n (%) 111 96% 38 95% 291 98%
Grade 8 and above, n (%) 95 82% 34 85% 251 84%
Unmarried, n (%) 69 59% 24 60% 169 57%
Employed at diagnosis, n (%) 60 52% 20 50% 168 56%
Had informal carers in post-diagnosis period, n (%) 56 48% 22 55% 111 37%
Missed work in post-diagnosis period, n (%) 36 31% 11 28% 37 12%
Median CD4 count at last test (IQR) 125 275 244 216
Median monthly income at diagnosis (2012 USD) (IQR) $150 381 $88 342 $135 312
Median days from diagnosis to interview (IQR) 115 28 119 32 115 33
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on special foods alone represented an average of 30, 13 and 27% of
total income for HIV-only, TB-only and TB/HIV participants, re-
spectively. None of the interviewed participants incurred direct med-
ical costs at the study clinic, or at any other PHC clinic. Participants
who sought care from health facilities outside the public health sys-
tem, particularly those with TB/HIV, incurred some direct medical
costs; an average of $1.71 per month was observed for TB/HIV par-
ticipants. The highest direct medical costs from providers outside
the public health system were incurred by participants accessing
care from traditional healers, however this was driven by one par-
ticipant reporting a very high cost of $415.
Indirect costs were high for all participant groups, particularly
those participants being treated for TB. Job loss and other income
losses were major drivers for indirect costs; accounting for 62% of
cost in the participants with TB/HIV and 77% of cost for TB-only
participants. Participants with TB (both TB-only and TB/HIV) lost
an average of $32.53/month in income due to time spent seeking
care. HIV-only participants lost substantially less income due to
seeking care on average than other participant groups, at an average
of $2.99/month.
About 4% of participants with TB and 3% of those with HIV
lost their job entirely due to illness. Among those who lost their jobs
due to illness, the mean and median income losses were $321.62 and
$207.90, respectively. The average income loss due to job loss across
all participants was $17.78/month for TB-only participants, $15.40/
month for TB/HIV participants and $2.99/month for HIV-only par-
ticipants. The monetary value of time lost by guardians was particu-
larly high for HIV-only participants. Table 3 shows the monthly
guardian opportunity costs of time varying from $2.07 in the TB/
HIV group to $4.14 in the HIV-only group. In contrast, the cost of
informal caregiving was particularly high for participants with
TB (regardless of HIV status); this cost averaged $5.81 per month
for TB-only participants and $4.42 per month for TB/HIV
participants.
Patient time loss
The time that participants lost while travelling to health facilities
and accessing (and waiting for) care in the post-diagnosis period is
presented in Table 4. TB/HIV participants lost the most time, aver-
aging 91 h per participant over the post-diagnosis period. This was
more than the combined time loss of TB-only and HIV-only partici-
pants (33.8 and 23.4 h, respectively). The time lost by TB/HIV par-
ticipants was driven by long hospitalizations for 11 out of 116
(9.4%) participants who were hospitalized for an average of 17.7
nights over the post-diagnosis period. The average time loss for TB/
HIV participants not hospitalized was 50 h over the post-diagnosis
period. Travel time, particularly for visits to the study clinic, was
also substantial. TB/HIV participants lost an average of 20 h travel-
ling, while TB-only and HIV-only participants lost an average of 15
and 6 h travelling, respectively.
Catastrophic costs
Figure 1 illustrates the percentages of participants facing cata-
strophic cost, varying thresholds from 5 to 25%. All participants
had high rates of catastrophic expenditures, across thresholds. The
results show that >60% of all participants face catastrophic costs at
the 10% threshold. TB/HIV participants show the highest
Table 2. Visits to any health care provider in the post-diagnosis period, by participant group
Patient group TB/HIV TB-only HIV-only
(n ¼ 116) (n ¼ 40) (n ¼ 298)
Visit type TB/HIV
visits
TB
visits
HIV
visits
TB/HIV
visits
TB
visits
HIV
visits
TB/HIV
visits
TB
visits
HIV
visits
Study clinic visits, mean (SD) 5.0 (4.6) 10.9 (14.2) 2.2 (4.6) 0.8 (.6) 14.5 (14.6) 0.1 (.2) 0 0 4.4 (2.0)
Visits toa other providers, mean (SD) 0.3 (0.7) 0.2 (0.7) 0.6 (2.6) 0.1 (0.2) 0 0.2 (0.7)
Subtotal, all providers, mean 5.0 11.2 2.2 0.8 15.1 0.1 0 0 4.6
Total visits, all visit types, all providers 18.4 16.0 5.1
Note: SD, standard deviation.
aOther public clinic, pharmacy, general practitioner, hospital-outpatient, hospital-inpatient and traditional healers.
Table 3. Monthly direct and indirect costs (USD 2013), by partici-
pant group
TB/HIV TB-only HIV-only
(n ¼ 116) (n ¼ 40) (n ¼ 298)
Mean (SD) Mean (SD) mean (SD)
Direct costs
Patient medical
Study clinic 0.00 0.00 0.00 0.00 0.00 0.00
Any other facility 1.71 10.23 0.07 0.42 0.87 4.12
Patient travel
Study clinic 4.12 8.91 1.69 3.31 1.25 3.07
Any other facility 0.63 2.89 0.05 0.20 0.24 1.37
Guardian travel
Study clinic 0.43 2.37 0.00 0.00 0.27 2.78
Any other facility 0.51 3.11 0.00 0.00 0.17 1.52
Food
Hospital 0.26 1.31 0.00 0.00 0.04 0.47
Special foods 13.14 17.33 8.06 11.05 9.76 14.91
Loan interest 0.93 9.78 0.00 0.00 5.68 89.11
Total direct costs 21.72 (29%a) 9.86 (14%a) 18.28 (45%a)
Indirect costs
Patient income loss
Job loss income loss 15.40 126.17 17.78 76.69 2.99 24.30
Care-seeking
income loss
30.45 105.56 34.60 98.99 13.81 59.03
Opportunity costs of time
Guardian
Study clinic 1.13 2.37 0.23 0.00 3.92 2.78
Any other facility 0.94 6.16 0.04 0.24 0.22 1.24
Carer 4.42 11.35 5.81 13.52 1.19 5.77
Total indirect costs 52.34 (71%a) 58.47 (86%a) 22.13 (55%a)
Grand total 74.07 68.33 40.41
Note: SD, standard deviation.
aPercentage of the overall total.
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proportions facing catastrophic costs, with 73% of participants en-
countering catastrophic costs at the 5% threshold and 61% at the
25% threshold; >70% of HIV-only participants experienced cata-
strophic at 5% threshold, however this proportion dropped at
higher thresholds. Considering only direct costs reduced the propor-
tion of participants encountering catastrophic costs to 68–50% of
TB/HIV participants, 46–31% of TB-only participants and 54–33%
of HIV-only participants depending on threshold (Supplementary
Figure S1).
Coping strategies
Table 5 shows the range of strategies adopted by participants and
their households to cope with income loss and/or direct out of
pocket payments incurred due to TB and/or HIV (Table 5). Fifteen
percent of HIV-only participants, 6% of TB/HIV participants and
8% of TB-only participants adopted at least one coping strategy.
The most common coping strategy was loan-taking, which was done
by 11% of HIV-only participants, 8% of TB-only participants and
3% of TB/HIV participants. Interest charged on loans to the TB/
Table 4. Total time loss in post-diagnosis period (hours), by participant group
TB/HIV TB-only HIV-only
(n ¼ 116) (n ¼ 40) (n ¼ 298)
mean (SD) Mean (SD) mean (SD)
Study clinic Consulting 28.2 27.7 17.5 17.3 13.9 11.7
Travel 20.7 20.7 15.4 17.3 5.6 6.4
Subtotal 48.9 (54%) 32.9 (97%) 19.6 (83%)
Other clinic Consulting 0 0.2 0.3 1.0 0.1 0.5
Travel 0.1 0.5 0.5 1.4 0.2 1.3
Subtotal 0.1 (0%) 0.8 (2%) 0.2 (1%)
Pharmacy Consulting 0 0.2 0 0.1 0 0.4
Travel 0 0.3 0 0.1 0.1 0.4
Subtotal 0.1 (0%) 0 (0%) 0.1 (0%)
General practitioner Consulting 0.1 0.7 0 0.3 0.3 1.8
Travel 0.2 1.2 0 0 0.2 0.8
Subtotal 0.3 (0%) 0 (0%) 0.4 (2%)
Hospital-inpatient Consulting 40.3 146.8 0 0 2.9 25.5
Travel 0.3 1.0 0 0 0.1 0.7
Subtotal 40.6 (45%) 0 (0%) 3.0 (13%)
Hospital-outpatient Consulting 0.2 1.0 0 0 0 0
Travel 0.5 3.2 0 0 0 0
Subtotal 0.7 (1%) 0 (0%) 0 (0%)
Traditional healer Consulting 0 0.3 0 0 0 0.2
Travel 0.1 0.8 0 0 0.1 0.9
Subtotal 0.1 (0%) 0 (0%) 0.2 (1%)
Grand total 90.8 33.8 23.4
Note: SD, standard deviation.
Figure 1. Catastrophic costs due to illness, by participant group
6 Health Policy and Planning, 2017, Vol. 0, No. 0
HIV and HIV-only group were relatively high, at 27 and 22% of the
initial value, respectively. In contrast, TB-only participants were
able to source loans at zero interest from friends or family.
Government grants and charitable donations were rarely accessed
across all participant groups. Similarly, asset sales were not used by
the majority of participants as a means to cope with TB and/or HIV-
related costs.
Discussion
All participants interviewed in this study encountered high costs
associated with HIV and/or TB. Over 45% of all participants experi-
enced catastrophic costs even at thresholds as high as 25% of indi-
vidual income. People with both TB and HIV on average face higher
levels of post-diagnosis catastrophic costs than those with TB-only
or HIV-only, especially at higher thresholds.
In principle, integration has the potential to reduce the overall
number of visits. We found many participants were receiving inte-
grated care, defined as receiving multiple services at the same facility
on the same day. TB/HIV participants received an average of five
‘integrated’ TB/HIV visits in the post-diagnosis period, where both
TB and HIV services were delivered on the same day. As a result,
participants received fewer TB-only visits than the TB-only group,
and fewer HIV-only visits than the HIV-only group. However, the
total time loss for TB/HIV participants was still considerably higher
than time loss for other participants. Similarly, travel costs for peo-
ple with TB/HIV were substantially higher than all other partici-
pants. Given the high costs faced by those with TB/HIV, further
gains may be achieved by ensuring that ‘integrated’ visits are de-
livered by the same provider or within the same room, reducing
waiting periods between multiple visits in a day.
The reduced visits observed for people with both TB and HIV
may be extended by further integration, where services are provided
within the same visit, minimizing the need for separate appoint-
ments. However, given the existing level of integration in terms of
numbers of joint TB/HIV visits, it is unlikely that catastrophic cost
can be averted by integration alone, and our results point to the
need for timely social protection schemes such the government tem-
porary disability grant, particularly for HIV-positive people starting
TB treatment.
To some degree, patients are able to cope with the costs of care,
for example, through taking loans with little or no interest from
family and friends. However, where costs are particularly high or
where patients lack social capital, coping strategies may place pa-
tients at risk of worsened long-term economic burden. For example,
access to loans in some instances can show a level of credit worthi-
ness; particularly where loans are taken from family or friends with
no interest they have been regarded in the literature as an indicator
of social capital and a possible way for households to reduce the
economic burden of illness (Chuma et al. 2007). However, where
loans are taken out with high interest rates or where productive
assets are sold, households face the risk of long-term economic hard-
ship (Madan et al. 2015). The extent of loan-taking at high interest
in order to meet the costs of health care suggests that people with
HIV may be at high risk of long-term economic hardship. People
with HIV were also more likely to sell assets in order to pay for care;
this may also translate to diminished financial status because assets
may have been sold for less than their replacement values.
In addition to loans and asset sale, some people received grants
and donations to deal with costs of illness. Currently, the South
African government offers a temporary social relief of distress grant
for patients who at the discretion of a doctor are deemed unfit to
undertake remunerative work (Department of Social Development
2006). However, access to these were consistently low, with 1% of
participants overall accessing government grants. People with TB in
particular had little access to the temporary disability grant, even
when they were encountering catastrophic costs. This may be due to
difficulty accessing the required certifications of disability within a
rapid time frame. Access to charitable donations was similarly low,
with only 4 of the 454 participants interviewed accessing a dona-
tion. This notable absence of donations and grants for all partici-
pants, and TB participants in particular, shows a policy
implementation gap for the most vulnerable TB patients. Further re-
search on the reasons for this implementation gap is needed, and the
South African government should thus consider alternative social
protection mechanisms, such as unconditional immediate cash trans-
fers to TB patients to close this gap (Boccia et al. 2011).
Participants with HIV (both HIV-only and TB/HIV) encoun-
tered relatively high costs due to accompaniment by guardians to
the study facility. South African HIV treatment policy encourages
use of a ‘treatment buddy’ to support adherence; however, this is
not considered a requirement for initiation onto treatment (South
African Department of Health 2010). Nearly all HIV-only partici-
pants reported that a guardian accompanied them to their most re-
cent PHC clinic visit. Participants with TB-only were not as
frequently accompanied to the PHC clinic and therefore had rela-
tively lower costs.
Our study supports previous findings that the primary drivers of
TB patient costs are income and job loss associated with time spent
care-seeking and inability to work due to illness (Muniyandi et al.
2005; Aspler et al. 2008; Ukwaja et al. 2013; Chimbindi et al.
Table 5. Coping strategies, by participant group
TB/HIV TB-only HIV-only
(n ¼ 116) (n ¼ 40) (n ¼ 298)
Grants and donations
Patients receiving government grants n (%) 1 (1%) 0 5 (2%)
Patients receiving charitable donations n (%) 0 (%) 0 4 (1%)
Asset sale
Patients selling assets n (%) 3 (3%) 0 7 (2%)
Mean value of assets sold (USD) $11.54 – $9.15
Loans
Patients taking loans n (%) 4 (3%) 3 (8%) 34 (11%)
Mean interest on loans (% of initial withdrawal) 27% 0% 22%
Total adopting any coping strategy 7 (6%) 3 (8%) 46 (15%)
Total adopting multiple strategies 1 (1%) 0 4 (1%)
Health Policy and Planning, 2017, Vol. 0, No. 0 7
2015). All people with TB had high numbers of health facility visits
and these were reflected in time and travel costs. Study participants
with TB also had a high rate of job loss, no matter their HIV status.
South Africa is currently scaling-up community based approaches to
treatment supervision that may reduce these costs in the future.
Our study also supports previous findings that supplementary food
is an important driver of TB patient costs in South Africa (Bond et al.
2008; Foster et al. 2015), raising the question of whether patients are
getting appropriate education regarding nutrition and TB. Previous
studies have indicated that patients may perceive that TB and HIV drugs
must be supplemented with higher food intake, often including foods
outside of the normal South African diet including eggs, fruit, soft
drinks, and meat (Bond et al. 2008). Improved nutrition counselling for
people with TB and/or HIV is needed to help households meet dietary
needs within their normal spending capabilities.
As with any patient-level costing effort, this study faced several
methodological limitations. Primarily, our comparisons are made on
a small sample and the participant groups we compared did not
have equal numbers of participants because eligible participants
were recruited consecutively, and the MERGE study had fewer par-
ticipants with TB. Methodological choices taken in this study, and
the potential limitations of these are discussed in detail by Sweeney
et al. (2016). In practice, when conducting patient cost interviews
alongside intervention studies and trials, analysts are faced with ei-
ther obtaining comprehensive costs of a smaller sample or limited
costs (usually OOP) from a larger sample. Due to the importance of
indirect costs as highlighted by previous studies, we chose the for-
mer. We chose a recall period of 3–5 months; this poses some risk of
recall bias, which we weighed against the potential to miss costs.
Second, the patient costs questionnaire was time consuming taking
up to 60 min. The long survey times required pose some risk of sur-
vey fatigue for interviewees, as well as interviewers. A number of
training sessions were conducted with the interviewers and a num-
ber of recruitment guides were developed to make the recruitment
process more feasible. Finally there is considerable debate in the lit-
erature surrounding the measurement of indirect costs, and the ap-
proach taken in previous studies is inconsistent (Zhang et al. 2011;
Krol et al. 2013; Krol and Brouwer 2014; Laurence et al. 2015). We
chose to report income loss as our primary measure of indirect cost
in order to avoid double-counting and possible bias against people
with zero income, and report on time loss separately to facilitate
comparison with other studies (Wingfield et al. 2014; Chimbindi
et al. 2015). Further methodological research on measurement of in-
direct costs would facilitate future analyses of patient costs.
Conclusions
Given the catastrophic costs associated with TB and HIV, even in
settings where TB and HIV treatment are provided for ‘free’, social
and income protection policies are likely to be required to protect
these patients if global targets on catastrophic cost reduction are to
be met. Integration of services has potential to reduce the number of
visits to the health facility, and our data shows patients are receiving
this care already in South Africa. However, we also find that those
with TB/HIV suffer the highest costs, and integration should be fur-
ther extended to ensure that both the economic burden of ill-health
and that of treatment are minimized for vulnerable households.
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